Kathryn Amacher, DO
Geriatric Medicine · Fairfield, CANPI 1366545568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 55.2% of the total.
Across 3 payments — averaging $84.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$140
- Acadia Pharmaceuticals Inc$64
- Otsuka America Pharmaceutical, Inc.$49
What the payments were for
- Food & beverage$254100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 1 | $140 |
| Acadia Pharmaceuticals Inc | 1 | $64 |
| Otsuka America Pharmaceutical, Inc. | 1 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$140
How this compares
$254 in reported general payments places this provider in the 60th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 495 | $171,800 |
| OzempicSemaglutide | 76 | $79,016 |
| XareltoRivaroxaban | 186 | $62,518 |
| JanuviaSitagliptin Phosphate | 169 | $59,559 |
| JardianceEmpagliflozin | 113 | $46,354 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $35,198 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,009 |
| NamzaricMemantine Hcl/Donepezil Hcl | 33 | $18,545 |
| ProcritEpoetin Alfa | 18 | $15,379 |
| Budesonide ErBudesonide | 23 | $13,570 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 392 | $10,428 |
| Gabapentin | 526 | $10,416 |
| TradjentaLinagliptin | 27 | $10,152 |
| Divalproex Sodium | 191 | $9,670 |
| BrilintaTicagrelor | 29 | $9,669 |
Paid to pharmacies, not to this prescriber.
Other geriatric medicine in Fairfield
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
- Douglas ZhangSan Leandro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.